comparemela.com

Latest Breaking News On - Dermatology physician assistants - Page 1 : comparemela.com

What Makes JAK Inhibitors Safe in Dermatology

Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.

Matthew zirwasSociety of dermatology physician assistantsDermatology physician assistantsGreater columbus

Potential JAK Inhibitor Combination Regimens in Dermatology

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

Matthew zirwasSociety for dermatology physician assistantsDermatology physician assistantsGreater columbus

The JAK Inhibitor Safety Conversation

Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.

Matthew zirwasDrug administrationSociety for dermatology physician assistantsDermatology physician assistantsGreater columbus

Secukinumab and Bimekizumab for Hidradenitis Suppurativa

Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.

Jenniferl hsiaoSociety for dermatology physician assistantsKeck school of medicineDrug administrationDermatology physician assistantsKeck schoolHidradenitis suppurativa clinical response

How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

Jenniferl hsiaoJohn frewDrug administrationKeck school of medicineSociety for dermatology physician assistantsDermatology physician assistantsKeck schoolHidradenitis suppurativa clinical response

vimarsana © 2020. All Rights Reserved.